Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wayne Tam

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
Blood Advances|December 5, 2025
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosisXue Kong, Zijun Y Xu-Monette, Zhenming Xu, et al.
Journal for Immunotherapy of Cancer|October 24, 2019
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesZijun Y Xu-Monette, Jianyong Li, Yi Xia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Li Wei, Xiaosheng Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2023
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCLZijun Y Xu-Monette, Yong Li, Thomas Snyder, et al.
JCO Precision Oncology|January 23, 2023
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology GroupMiguel D Cantu, Rashmi Kanagal-Shamanna, Sa A Wang, et al.
Cancer Discovery|October 14, 2016
CREBBP Inactivation Promotes the Development of HDAC3-Dependent LymphomasYanwen Jiang, Ana Ortega-Molina, Huimin Geng, et al.
Journal of Hematology & Oncology|November 5, 2020
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Mingzhi Zhang, Zijun Y Xu-Monette, et al.
Oncoimmunology|August 5, 2021
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphomaHua You, Zijun Y Xu-Monette, Li Wei, et al.
Nature Materials|March 17, 2023
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomasShivem B Shah, Christopher R Carlson, Kristine Lai, et al.
Oncoimmunology|August 7, 2024
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphomaZijun Y Xu-Monette, Cancan Luo, Li Yu, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Blood Advances|December 5, 2025
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosisXue Kong, Zijun Y Xu-Monette, Zhenming Xu, et al.
Journal for Immunotherapy of Cancer|October 24, 2019
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapiesZijun Y Xu-Monette, Jianyong Li, Yi Xia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2022
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Li Wei, Xiaosheng Fang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2023
Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCLZijun Y Xu-Monette, Yong Li, Thomas Snyder, et al.
JCO Precision Oncology|January 23, 2023
Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology GroupMiguel D Cantu, Rashmi Kanagal-Shamanna, Sa A Wang, et al.
Cancer Discovery|October 14, 2016
CREBBP Inactivation Promotes the Development of HDAC3-Dependent LymphomasYanwen Jiang, Ana Ortega-Molina, Huimin Geng, et al.
Journal of Hematology & Oncology|November 5, 2020
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Mingzhi Zhang, Zijun Y Xu-Monette, et al.
Oncoimmunology|August 5, 2021
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphomaHua You, Zijun Y Xu-Monette, Li Wei, et al.
Nature Materials|March 17, 2023
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomasShivem B Shah, Christopher R Carlson, Kristine Lai, et al.
Oncoimmunology|August 7, 2024
DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphomaZijun Y Xu-Monette, Cancan Luo, Li Yu, et al.
Pageof 14